Value Proposition:
· Technology combines positron emission tomography (PET) with targeted imaging compounds for a first-in-class approach to peripheral nerve injury (PNI) evaluation and monitoring.
· Provides a method for non-invasive evaluation of PNI status immediately post-injury and over the recovery timeline.
· Implementation...
Value Proposition:
· Quantification and PET imaging of microglial cells in the brain
· Diagnostic for neuroinflammatory disorders – Alzheimer’s and MS
· Favorable compound half-life enables shipping
· Potential for non-CNS applications
Technology Description
Researchers at Johns Hopkins have developed a series of Positron...
Unmet Need
Neurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...
Unmet Need
Peripheral nerve injuries require optimally timed intervention to maximize functional recovery and minimize permanent nerve death and negative impacts to quality of life. Current treatment plans rely primarily on monitoring for spontaneous healing or an indication that there must be surgical intervention, an approach that hinges on accurate...
Unmet Need
Each year in the United States, ~82,000 patients are diagnosed with renal cell carcinoma (RCC), and there are ~15,000 RCC-related deaths (1). 75-85% of these cancers are subtyped as clear cell renal cell carcinoma (ccRCC) (2). ccRCC is characterized by overexpression of carbonic anhydrase IX (CAIX) (3). Researchers have previously developed...
Unmet Need
Parkinson’s Disease affects over 6 million people globally, and is one of the fastest growing neurodegenerative diseases in prevalence, disability, and deaths (GBD 2016 Parkinson’s Disease Collaborators). Presently, Parkinson’s diagnosis and prognosis depend on monitoring a patient’s symptoms and occasional imaging of the affected region...
Inventor(s): Yong Du, Kevin Leung, Martin Pomper, Steven Rowe
Unmet Need
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with approximately 60,000 Americans diagnosed with it each year. It is a progressive nervous system disorder that affects movement, from small tremors to a loss of automatic movements. One of the tools...
Unmet Need
Advances in medical imaging has radically changed the practice of medicine in the last few decades. Recently, machine learning techniques have been shown to produce higher fidelity images in various modalities and to aid in diagnostics (Lundervold & Lundervold, 2019). Machine learning imaging research require large datasets to be trained...
Unmet Need: Despite widespread research efforts, breast cancer remains the second leading cause of cancer deaths in women. There is an urgent need to identify novel biomarkers and treatment strategies against aggressive forms of breast cancer to improve prognosis and therapy.
Technical Details: Johns Hopkins researchers have identified a novel biomarker...
Unmet Need
SPECT and PET imaging are two modalities which are widely implemented for the diagnosis, research and management of many diseases. The quality of their images is depleted by noise and other factors, causing the images to suffer from low resolution and artifacts. In addition, current iterative reconstruction techniques are extremely time...
Unmet Need
Prostate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Various treatment strategies, including surgery, radiation and chemotherapy, exist for prostate cancer but their success depends on the stage of the cancer at diagnosis. Novel...
Unmet Need
Gene therapy can be a cure-all for genetic disorders, and can be a promising therapy for diseases such as cancer, neurodegenerative diseases, neurological disorders, heart disease or diabetes. The success of gene therapy is dependent on the safety, efficacy, and specificity of the treatment. The delivery vehicle, also known as a vector,...
Unmet Need
Gene therapy has the potential to offer a one-time cure for severe, debilitating diseases that were previously untreatable or required chronic therapy. While a few viral-based gene therapies have recently received FDA approval, safety concerns around viral-based gene therapies continue to limit their clinical development. Non-viral strategies...
Unmet Need
Prostate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. A promising precision cancer treatment known as photodynamic therapy (PDT) offers a way to selectively target prostate cancer cells for destruction. Prostate PDT uses a ligand to attach a light-sensitizing agent known as porphyrin...
Unmet Need
According to The American Cancer Society, approximately 1 in 9 men will be diagnosed with prostate cancer in their lifetime, with 174,650 new cases diagnosed yearly in the US. As prostate cancer is the second leading cause of cancer death in American men, early detection is important for adequate treatment. The most common method of detecting...
Unmet Need
Hepatocellular carcinoma (HCC) is the third leading cancer in the US with a ~twenty percent (20%) survival rate. HCC develops typically in the inflammatory environment of the liver caused by infections or liver disease. Therefore, it is essential to have highly targeted anti-cancer therapies to achieve clinical efficacy. Currently, viral...
Unmet Need
Chemogenetics is defined as a method by which proteins are made to interact with small molecules, typically neurological molecules, as they have never been interacted with before. There is a powerful and versatile approach for remote and momentary manipulation of cellular activity called Designer Receptors Exclusively Activated by Designer...
Unmet Need
Prostate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Elevated prostate-specific membrane antigen (PSMA) serves as a biomarker for prostate cancer and as well as primary clear cell renal carcinoma (ccRCC). However, PSMA is also...
Unmet Need
Prostate-specific membrane antigen (PSMA, also known as GCPII) is a validated target for prostate cancer imaging and therapy. Macromolecular reagents, most notably monoclonal antibodies (mAbs), offer a viable alternative to small-molecule PSMA ligands for imaging and therapy. However existing anti-PSMA antibodies have several drawbacks,...
Unmet Need:
Non-invasive assessment of tumor burden and cancer-selective treatment in prostate cancer. This approach is will allow visualization in real-time of the distribution and action of therapeutic agents in vivo by transducing the presence of PSMA at the tissue level to characteristic Raman spectral patterns. This nanoplex platform, therefore,...
